Literature DB >> 15794413

Toll-like receptors: dysregulation in vivo in patients with acute respiratory distress syndrome.

Nora E Ramírez Cruz1, Carmen Maldonado Bernal, María Luisa Cuevas Urióstegui, Jorge Castañoń, Constantino López Macías, Armando Isibasi.   

Abstract

OBJECTIVE: To determine the time course of the expression of five toll-like receptors (TLRs 1-5) in mixed blood mononuclear cells and their relationship to pro-inflammatory and anti-inflammatory cytokines during acute respiratory distress syndrome (ARDS).
MATERIAL AND METHODS: In a prospective, a longitudinal study was done at an intensive-care unit of a university-affiliated hospital. Seven consecutive patients with ARDS were studied. We followed the onset and progression of ARDS, and subsequent patient recovery or death, and compared patient data with data from a group of healthy volunteers. We separated mixed blood mononuclear cells using Ficoll-Hypaque to detect the transcripts of human TLRs 1-5. TLR mRNAs were isolated by semiquantitative reverse-transcription PCR (RT-PCR). Each signal was expressed as the ratio of TLR mRNA to beta-actin. Cytokines, including tumor necrosis factor alpha, interferon gamma, and interleukins 4, 6, 8, 10, and 12, were assayed using commercial ELISA kits.
RESULTS: Dysregulation in the transcription of TLRs gene, principally in ARDS surviving patients, was observed. Down-regulated expressions of TLR1, TLR4, and TLR5 mRNAs were observed in the first 24 h in patients who survived, and probably played a key role in the survival of patients with ARDS caused by sepsis. Serum levels of cytokines such as IL-6, 8 and 10 were significantly increased in patients with ARDS as compared with levels in the healthy volunteers. However, serum levels of IL-12 were lower in patients with ARDS than in the healthy volunteers. There was difference in serum cytokines concentration between survivors and non-survivors patients with ARDS (except for interleukin-10).
CONCLUSIONS: Thus, TLRs gene dysregulation and cytokine profiles are probably important prognostic factors for patient outcome and survival after ARDS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15794413

Source DB:  PubMed          Journal:  Rev Alerg Mex        ISSN: 0002-5151


  6 in total

Review 1.  Role of Toll-like receptors in infection and immunity: clinical implications.

Authors:  Patricia Cristofaro; Steven M Opal
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Expression of triggering receptor on myeloid cell 1 and histocompatibility complex molecules in sepsis and major abdominal surgery.

Authors:  Nestor González-Roldán; Eduardo Ferat-Osorio; Rosalía Aduna-Vicente; Isabel Wong-Baeza; Noemí Esquivel-Callejas; Horacio Astudillo-de la Vega; Patricio Sánchez-Fernández; Lourdes Arriaga-Pizano; Miguel Angel Villasís-Keever; Constantino López-Macías; Armando Isibasi
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

3.  Resolution of Toll-like receptor 4-mediated acute lung injury is linked to eicosanoids and suppressor of cytokine signaling 3.

Authors:  Jan N Hilberath; Troy Carlo; Michael A Pfeffer; Roxanne H Croze; Frantz Hastrup; Bruce D Levy
Journal:  FASEB J       Date:  2011-02-14       Impact factor: 5.191

4.  Association of TLR5 sequence variants and mRNA level with cytokine transcription in pigs.

Authors:  X Yang; E Murani; S Ponsuksili; K Wimmers
Journal:  Immunogenetics       Date:  2012-11-07       Impact factor: 2.846

5.  Similarly Lethal Strains of Extraintestinal Pathogenic Escherichia coli Trigger Markedly Diverse Host Responses in a Zebrafish Model of Sepsis.

Authors:  Amelia E Barber; Brittany A Fleming; Matthew A Mulvey
Journal:  mSphere       Date:  2016-04-20       Impact factor: 4.389

Review 6.  Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential.

Authors:  Philippe Md Potey; Adriano G Rossi; Christopher D Lucas; David A Dorward
Journal:  J Pathol       Date:  2019-02-15       Impact factor: 7.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.